Ramsay Générale de Santé (ENXTPA:GDS) has called a board meeting for 6 October 2026 to review the auditors' certification report on its consolidated accounts, a routine governance step that remains important for equity holders.
Against that routine backdrop, Ramsay Générale de Santé's share price has moved around this year, with a 7 day share price return of 2.89% and a 90 day share price return that is down 11.07%. The 1 year total shareholder return of 6.87% follows a much weaker 3 year total shareholder return that is down 53.24%, which points to only tentative momentum as the stock trades at €9.96.
Scan Ramsay Générale de Santé alongside other hospital and healthcare operators that screen as potential value ideas by reviewing our hand picked 174 high quality undervalued stocks .
The share price has recovered slightly but still sits far below some valuation estimates. Does that gap hint at mispricing in Ramsay Générale de Santé, or does it simply reflect the risks now baked into €9.96?
Preferred Price-to-Sales of 0.2x: Is it justified?
Ramsay Générale de Santé trades on a P/S of roughly 0.2x while the last close sits at €9.96, a combination that screens as cheap relative to peers and sector.
P/S compares the market value of the equity to the revenue the business generates. For a hospital operator like Ramsay Générale de Santé that runs over €5.3b in annual revenue, investors often use this yardstick when earnings are loss making or volatile because sales tend to be more stable than profits.
The current read is clear. The stock is described as good value versus similar French healthcare operators on this preferred multiple, and it is also flagged as trading about 69% below the future cash flow value estimate of €32.15 in our DCF work. Taken together, this indicates the market is pricing in meaningful risk around profitability, leverage and earnings quality rather than giving full credit to the current revenue base.
The same pattern shows up against the wider European Healthcare group where the P/S of 0.2x sits far below the 0.8x industry average. The gap is wide, which means the market is applying a heavy discount to each euro of sales compared with regional peers that share similar end markets.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-Sales of 0.2x (UNDERVALUED)
Still, Ramsay Générale de Santé faces clear pressure points, including a net loss of €41.5m and significant exposure to regulated European healthcare funding.
Find out about the key risks to this Ramsay Générale de Santé narrative .
Another View on Ramsay Générale de Santé's Value
The earlier discussion focused on Ramsay Générale de Santé's low P/S, which flags the equity as cheap against French and European healthcare peers. A second lens comes from the SWS DCF model, which points to a future cash flow value of €32.15 per share versus the current €9.96.
That gap implies the stock trades about 69% below this fair value estimate, so the model treats today's quote as heavily discounted. The question for any holder is straightforward: Are the funding risks, losses and governance concerns enough to justify such a wide cushion, or is the market overshooting on fear?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out Ramsay Générale de Santé for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 174 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed signals around Ramsay Générale de Santé's valuation and risk profile can feel messy, so consider moving quickly and stress testing the numbers yourself using the 1 key reward and 2 important warning signs .
Looking for more investment ideas beyond Ramsay Générale de Santé?
If Ramsay Générale de Santé has sharpened your focus on price versus fundamentals, use the screener to quickly spot other opportunities that fit your playbook.
-
Target potential turnaround stories by reviewing 126 elite penny stocks with strong financials that already clear basic financial quality hurdles.
-
Zero in on potential mispricings by scanning our 618 high quality undiscovered gems before they attract wider market attention.
-
Lean toward resilience by filtering for 222 resilient stocks with low risk scores that pair steadier risk scores with more robust fundamentals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GDS.PA .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
